knowledge -WSS

knowledge

author：explore 2025-10-01 17:57:24 - browse：1979

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Oprah kicked off a national conversation on obesity. Let's have it

WSS

There's no autism epidemic. It's an autism diagnosis epidemic

Merck drug for rare lung condition set for approval in U.S.

There's no autism epidemic. It's an autism diagnosis epidemic

Ebola vaccine can save some who are already sick, per new study

Supreme Court mifepristone arguments center on docs' right to sue

Eli Lilly reports tirzepatide MASH success during Q4 earnings

focus

knowledge

knowledge

United colonoscopy coverage change 'may cost lives,' doctors say

The Readout: Lenmeldy, GLP

State Dept. review finds Biden bears some blame for Afghanistan failures

Latigo launches with $135 million for Vertex

The high cost of giving birth even with insurance

The Readout: Lenmeldy, GLP

23andMe had bad news about my health. I wish a person had delivered it

Covid vaccine financial winners and losers, from Pfizer to Novavax

Medical leaders decry Supreme Court decision on affirmative action

Readout LOUD podcast: mifepristone case, GLP

explore

Congress considering partial increase for doctor pay in Medicare

Decaf coffee targeted by food safety group under obscure FDA rule

Washington mulls new rules to avert another Change Healthcare

Abortion pill Supreme Court ruling could impact entire drug industry

Eliminate the waiting period for sterilization covered by Medicaid

Abortion pill Supreme Court ruling could impact entire drug industry

Wikipedia

Wikipedia

focus

hotspot